Xin Lang Cai Jing·2025-11-06 02:06Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and changes in shareholder composition, reflecting its ongoing developments in the biopharmaceutical sector and market dynamics [1][3][4]. Financial Performance - As of September 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion yuan, representing a year-on-year growth of 42.27% [3]. - The company recorded a net profit attributable to shareholders of -551 million yuan, which is a 48.60% increase compared to the previous period [3]. Stock Market Activity - On November 6, 2023, the stock price of Rongchang Biopharmaceuticals fell by 2.00%, trading at 90.16 yuan per share with a total market capitalization of 50.815 billion yuan [1]. - The stock has seen a year-to-date increase of 199.44%, with a recent 5-day increase of 1.69% and a 20-day decrease of 12.86% [1]. Shareholder Composition - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, while the average number of circulating shares per person decreased by 15.54% to 10,639 shares [3]. - The top ten circulating shareholders include significant players such as Hong Kong Central Clearing Limited and Wanjiayouxuan, with notable changes in their holdings [4].